From Vial To Value: How GLP-1s Are Redefining Injectable Care For Chronic Conditions

GLP‑1 therapies are rapidly reshaping expectations for chronic care injectables, driving a shift toward patient‑friendly delivery systems that can be used safely at home. As demand accelerates, manufacturers face growing pressure to expand capacity, adapt to diverse formulation needs, and support advanced formats such as autoinjectors, wearable injectors, and emerging microneedle patches.

These technologies promise greater ease of use, improved adherence, and, in some cases, a reduced cold‑chain burden—yet they also introduce new complexities in design, scalability, and regulatory compliance. The expanding market highlights the strategic role of CDMOs, whose expertise now spans device selection, fill‑finish excellence, and combination‑product readiness.

Access the full white paper to explore how shifting patient expectations and evolving delivery technologies are redefining the injectable landscape.